Based on these, selective inhibition of BRAF has been shown to induce an activated CD8+ T cell infiltrate, as well as increase melanoma MHC expression and melanoma antigen presentation early during treatment both in preclinical models and in human melanoma tissue samples (159–161). Here, CD8A is linked to melanoma.